[go: up one dir, main page]

PE20081553A1 - Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide - Google Patents

Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide

Info

Publication number
PE20081553A1
PE20081553A1 PE2008000036A PE2008000036A PE20081553A1 PE 20081553 A1 PE20081553 A1 PE 20081553A1 PE 2008000036 A PE2008000036 A PE 2008000036A PE 2008000036 A PE2008000036 A PE 2008000036A PE 20081553 A1 PE20081553 A1 PE 20081553A1
Authority
PE
Peru
Prior art keywords
monoclonal antibody
treatment
pharmaceutical composition
rheumatoid arthritis
composition including
Prior art date
Application number
PE2008000036A
Other languages
English (en)
Inventor
Casimiro Jose Enrique Montero
Parada Angel Raimundo Casaco
Herrera Zaima Mazorra
Ramirez Ruby Alonso
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20081553A1 publication Critical patent/PE20081553A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN ANTICUERPO MONOCLONAL ANTI-CD6 T1h PRODUCIDO POR EL HIBRIDOMA IOR-T1A. ADICIONALMENTE PUEDE CONTENER UN AGENTE QUIMIOTERAPEUTICO TAL COMO METROTEXATO, ANTICUERPO MONOCLONAL ANTI CD-20, FACTOR DE NECROSIS TUMORAL ALFA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE
PE2008000036A 2006-12-26 2008-01-02 Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide PE20081553A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060250 2006-12-26

Publications (1)

Publication Number Publication Date
PE20081553A1 true PE20081553A1 (es) 2008-12-10

Family

ID=39562112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000036A PE20081553A1 (es) 2006-12-26 2008-01-02 Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide

Country Status (19)

Country Link
US (3) US20100092423A1 (es)
EP (1) EP2119452B1 (es)
KR (1) KR101482956B1 (es)
CN (2) CN101657215A (es)
AR (1) AR064527A1 (es)
AU (1) AU2007336563B2 (es)
CA (1) CA2676185C (es)
DK (1) DK2119452T3 (es)
ES (1) ES2785043T3 (es)
HK (1) HK1213782A1 (es)
IT (1) ITTO20070942A1 (es)
MY (1) MY165625A (es)
NZ (1) NZ578635A (es)
PE (1) PE20081553A1 (es)
PL (1) PL2119452T3 (es)
PT (1) PT2119452T (es)
RU (1) RU2472526C2 (es)
UY (1) UY30838A1 (es)
WO (1) WO2008077355A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2993186T3 (pl) * 2008-03-14 2020-02-28 Biocon Limited Przeciwciało monoklonalne i sposób jego otrzymywania
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
US11037196B2 (en) 2012-02-24 2021-06-15 Netclearance Systems, Inc. Interactive advertising using proximity events
US11062258B2 (en) 2012-02-24 2021-07-13 Netclearance Systems, Inc. Automated logistics management using proximity events
AU2014294616B2 (en) 2013-07-23 2019-07-11 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102584953B1 (ko) * 2015-03-13 2023-10-04 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 스클레로스틴 항체, 이의 항원 결합 단편 및 의학적 용도
EA201891800A1 (ru) * 2016-02-10 2019-01-31 Кайман Кемикал Компани Инкорпорейтед Антитела к цитруллинированным hla-полипептидам и их применение
PT3529274T (pt) 2016-10-21 2024-06-21 Biocon Ltd Um anticorpo monoclonal e um método de utilização para o tratamento de lúpus
US11334889B2 (en) 2016-11-29 2022-05-17 Netclearance Systems, Inc. Mobile ticketing based on proximity
US11151534B2 (en) * 2016-11-29 2021-10-19 Netclearance Systems, Inc. Consumer interaction module for point-of-sale (POS) systems
CN109903854B (zh) * 2019-01-25 2023-04-07 电子科技大学 一种基于中医药文献的核心药物识别方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
CA2175247A1 (en) * 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
US5423562A (en) * 1993-11-05 1995-06-13 Pearce, Jr.; Fredric C. Chair lift
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
EP0888292B1 (fr) * 1996-03-20 2001-10-31 Aventis Pharma S.A. COMPOSES TRICYCLIQUES AYANT UNE ACTIVITE VIS-A-VIS DES INTEGRINES NOTAMMENT VIS-A-VIS DE L'INTEGRINE ALPHA vBETA3, LEUR PROCEDE DE PREPARATION ET LES INTERMEDIAIRES DE CE PROCEDE, LEUR APPLICATION A TITRE DE MEDICAMENTS ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
FI110553B (fi) * 2001-02-12 2003-02-14 Perlos Oyj Liitin ja liittimen irtopala
ES2192128B1 (es) * 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
WO2006035876A1 (ja) * 2004-09-29 2006-04-06 Kowa Co., Ltd. 関節リウマチの予防及び／又は治療薬
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체

Also Published As

Publication number Publication date
AU2007336563A1 (en) 2008-07-03
EP2119452A4 (en) 2012-06-06
CA2676185C (en) 2013-03-12
NZ578635A (en) 2012-03-30
AU2007336563B2 (en) 2012-11-01
US20160024220A1 (en) 2016-01-28
WO2008077355A1 (es) 2008-07-03
ES2785043T3 (es) 2020-10-05
HK1213782A1 (zh) 2016-07-15
CN101657215A (zh) 2010-02-24
US20170066835A1 (en) 2017-03-09
EP2119452B1 (en) 2020-03-04
MY165625A (en) 2018-04-18
KR101482956B1 (ko) 2015-01-15
EP2119452A1 (en) 2009-11-18
ITTO20070942A1 (it) 2008-06-27
UY30838A1 (es) 2008-07-31
US20100092423A1 (en) 2010-04-15
PT2119452T (pt) 2020-05-08
PL2119452T3 (pl) 2021-03-08
DK2119452T3 (da) 2020-04-20
KR20090122910A (ko) 2009-12-01
CA2676185A1 (en) 2008-07-03
CN105251004A (zh) 2016-01-20
AR064527A1 (es) 2009-04-08
RU2472526C2 (ru) 2013-01-20
RU2009128659A (ru) 2011-02-10

Similar Documents

Publication Publication Date Title
PE20081553A1 (es) Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
PE20161327A1 (es) Proteinas de enlace al antigeno il-23 humana
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
UA109658C2 (xx) Антитіло проти cgrp
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
CL2008003416A1 (es) Anticuerpo monoclonal anti-anexelekto (axl); hibridoma; inhibidor de la angiogenesis, supresor del crecimiento celular, inductor de la actividad de fosforilacion de axl, agente que reduce el nivel de expresion de axl, agente anti-cancer que lo comprenden; y metodo para reducir el nivel de expresion de axl.
PE20080911A1 (es) Anticuerpo anti-vegf
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
AR085591A1 (es) Anticuerpos del antigeno carcinoembrionario humano (cea)
CL2009000618A1 (es) Uso de anticuerpo monoclonal humanizado th1, que reconoce el dominio 1 del cd6 humano, para preparar un medicamento útil en el tratamiento de la diabetes tipo-1.
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
NZ606195A (en) Methods and compositions for liver cancer therapy
CL2012000623A1 (es) Compuestos derivados de 4-[4,4-dimetil-5oxo-3-(piridin-ilmetil)-2-tioxoimidazolidin-1-il]-2-(trifluorometil)benzonitrilo, con propiedades antiandrogenicas; metodo de preparacion; composcion farmaceutica; y su uso para el tratamiento y/o profilaxis de cancer de prostata.
PE20091655A1 (es) Farmaco para el cancer de higado
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
AR084234A1 (es) Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека

Legal Events

Date Code Title Description
FC Refusal